Upcoming - case studies of low-cost OTC drug sales performance post patent expiration & market exclusivity in European markets

Setting the foundation for estimating Moberg Pharma's terminal value

It’s been a good month. I hope readers have enjoyed it as much as I have. I didn’t quite expect Moberg’s shares to rally 45% two weeks after posting the writeup, but here we are. Nanocaps are volatile, eh?

This topic may feel as if I’m jumping the gun given the drugs patent expires in the 2030’s, but no stone will be left unturned. Also, I intuitively feel this is actually quite an important line of research given the durability of a company’s earnings is one of the most critical elements in determining a stocks multiple.

I can’t say when I’ll have this done, only that I’m working on it.

Thank you for your patience and support,

-Left